CA3066423A1 - Compounds for modulating s1p1 activity and methods of using the same - Google Patents

Compounds for modulating s1p1 activity and methods of using the same Download PDF

Info

Publication number
CA3066423A1
CA3066423A1 CA3066423A CA3066423A CA3066423A1 CA 3066423 A1 CA3066423 A1 CA 3066423A1 CA 3066423 A CA3066423 A CA 3066423A CA 3066423 A CA3066423 A CA 3066423A CA 3066423 A1 CA3066423 A1 CA 3066423A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
oxadiazol
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3066423A
Other languages
English (en)
French (fr)
Inventor
Philip Michael Pitis
Robert Eugene BOYD
Tamara Ann Miskowski DAUBERT
Michael John Hawkins
Guodong Liu
Aimee Crombie SPEERSCHNEIDER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trevena Inc
Original Assignee
Trevena Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevena Inc filed Critical Trevena Inc
Publication of CA3066423A1 publication Critical patent/CA3066423A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3066423A 2017-06-14 2018-06-12 Compounds for modulating s1p1 activity and methods of using the same Pending CA3066423A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762519575P 2017-06-14 2017-06-14
US62/519,575 2017-06-14
PCT/US2018/036989 WO2018231745A1 (en) 2017-06-14 2018-06-12 Compounds for modulating s1p1 activity and methods of using the same

Publications (1)

Publication Number Publication Date
CA3066423A1 true CA3066423A1 (en) 2018-12-20

Family

ID=64660688

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3066423A Pending CA3066423A1 (en) 2017-06-14 2018-06-12 Compounds for modulating s1p1 activity and methods of using the same

Country Status (10)

Country Link
US (2) US11912693B2 (de)
EP (1) EP3638235A4 (de)
JP (2) JP7252908B2 (de)
KR (1) KR20200020781A (de)
CN (1) CN110831593A (de)
AU (2) AU2018282747B2 (de)
BR (1) BR112019026478A2 (de)
CA (1) CA3066423A1 (de)
IL (1) IL271149B2 (de)
WO (1) WO2018231745A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
CA3052479A1 (en) * 2017-02-17 2018-08-23 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
MA48994A (fr) 2017-03-30 2020-02-05 Hoffmann La Roche Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
CA3066423A1 (en) 2017-06-14 2018-12-20 Trevena, Inc. Compounds for modulating s1p1 activity and methods of using the same
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
US20220079948A1 (en) * 2018-12-21 2022-03-17 Indiana University Research And Technology Corporation Compositions and methods for suppressing and/or treating hiv-infection and/or a related clinical condition thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
MX2021015510A (es) 2019-06-14 2022-04-11 Janssen Pharmaceutica Nv Pirazolo[4,3-b]piridinas sustituidas y su uso como moduladores del receptor glun2b.
KR20220024403A (ko) 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도
BR112021024856A2 (pt) 2019-06-14 2022-01-18 Janssen Pharmaceutica Nv Amidas pirazolo-piridina substituídas e seu uso como moduladores do receptor de glun2b
BR112021025132A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Carbamatos de piridina e seu uso como moduladores do receptor glun2b
EP3982958A1 (de) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituierte heteroaromatische pyrazolo-pyridine und ihre verwendung als glun2b-rezeptor-modulatoren
EP3983072A1 (de) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Pyrazincarbamate und ihre verwendung als glun2b-rezeptor-modulatoren
US20220257583A1 (en) * 2019-08-01 2022-08-18 Duke University Compositions and Methods for the Treatment of Intracranial Diseases
JP2022547079A (ja) * 2019-09-05 2022-11-10 トレベナ・インコーポレイテッド てんかんを治療する方法を使用しててんかんを治療する方法
EP4061352A4 (de) 2019-11-19 2024-02-28 Trevena, Inc. Verbindungen und verfahren zur herstellung von s1p1-modulierenden verbindungen
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
AU2021300429A1 (en) 2020-07-02 2023-02-16 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
JP2024506387A (ja) * 2021-02-10 2024-02-13 アイカーン スクール オブ メディスン アット マウント サイナイ 腎線維症を治療するためのオキサジアゾリルジヒドロピラノ［２，３‐ｂ］ピリジン系ＨＩＰＫ２阻害剤
EP4298099A1 (de) 2021-02-25 2024-01-03 Incyte Corporation Spirocyclische lactame als jak2-v617f-inhibitoren
TW202337453A (zh) 2022-03-17 2023-10-01 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之三環脲化合物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003681A2 (en) 1998-07-16 2000-01-27 Axys Pharmaceuticals, Inc. Process for the synthesis of benzopyran derivatives
ES2247271T3 (es) * 2001-04-04 2006-03-01 Pfizer Products Inc. Nuevos benzotriazoles como compuestos antiinflamatorios.
AU2003255803A1 (en) * 2002-08-23 2004-03-11 Celltech R And D Limited Quinazolinone derivatives
AU2003263323A1 (en) * 2002-09-07 2004-03-29 Celltech R And D Limited Quinazolinone derivatives
CA2499429C (en) 2002-09-18 2010-09-21 Pfizer Products Inc. Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
WO2006044505A2 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
US7919519B2 (en) 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
WO2007071598A1 (en) * 2005-12-23 2007-06-28 F. Hoffmann-La Roche Ag Aryl-isoxazolo-4-yl-oxadiazole derivatives
TWI382984B (zh) 2006-04-03 2013-01-21 Astellas Pharma Inc 雜環化合物
US7803940B2 (en) * 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
EP2304366A2 (de) 2008-05-30 2011-04-06 Foster Wheeler Energia Oy Verfahren und system zur erzeugung von energie durch oxyfuel-verbrennung
WO2009148452A1 (en) 2008-06-06 2009-12-10 Abbott Laboratories Novel 1,2,4 oxadiazole compounds and methods of use thereof
TW201000099A (en) * 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
JP2012505836A (ja) 2008-10-17 2012-03-08 アカール ファーマ ピーティーワイ リミテッド Ｓ１ｐ受容体モジュレーターおよびそれらの使用
TW201116212A (en) * 2009-10-29 2011-05-16 Du Pont Heterobicycle-substituted azolyl benzene fungicides
US9193697B2 (en) * 2010-04-08 2015-11-24 Merck Sharp & Dohme Corp. Oxazole derivatives useful as modulators of FAAH
MX339840B (es) * 2010-05-21 2016-06-14 Abbvie Inc * Moduladores de los receptores de 5-ht y metodos de uso de los mismos.
JP2013544811A (ja) 2010-11-03 2013-12-19 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および血管疾患の治療用のｓ１ｐ１アゴニストとしての複素環式化合物
KR102385359B1 (ko) 2010-11-08 2022-04-11 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
NZ716420A (en) * 2011-05-10 2017-05-26 Gilead Sciences Inc Fused heterocyclic compounds as sodium channel modulators
EP2766352B1 (de) * 2011-10-12 2018-06-06 University Health Network (UHN) Indazolverbindungen als kinasehemmer und verfahren zur krebsbehandlung damit
EP2671881A1 (de) * 2012-06-07 2013-12-11 Syngenta Participations AG. Pestizidaktive pyridyl- und pyrimidylsubstituierte Thiazolderivate
US9403845B2 (en) * 2012-08-20 2016-08-02 Syngenta Participations Ag Pesticidally active pyridyl- and pyrimidyl- substituted pyrazole derivatives
LT3035926T (lt) 2013-08-19 2020-11-25 The Regents Of The University Of California Junginiai ir būdai, skirti epileptinio sutrikimo gydymui
EP2853532B1 (de) * 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-Oxadiazoldrivate als allosterische Modulatoren von metabotropen Glutamatrezeptoren, die zur Gruppe-III gehören
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
UY36274A (es) * 2014-08-20 2016-02-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g
PT3310760T (pt) * 2015-06-22 2022-11-10 Arena Pharm Inc Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1
MX2018009173A (es) * 2016-02-01 2018-11-19 Ironwood Pharmaceuticals Inc Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash).
CA3066423A1 (en) 2017-06-14 2018-12-20 Trevena, Inc. Compounds for modulating s1p1 activity and methods of using the same
JP2022547079A (ja) 2019-09-05 2022-11-10 トレベナ・インコーポレイテッド てんかんを治療する方法を使用しててんかんを治療する方法
EP4061352A4 (de) 2019-11-19 2024-02-28 Trevena, Inc. Verbindungen und verfahren zur herstellung von s1p1-modulierenden verbindungen

Also Published As

Publication number Publication date
IL271149B1 (en) 2024-01-01
AU2018282747A1 (en) 2020-01-30
WO2018231745A1 (en) 2018-12-20
JP2023078375A (ja) 2023-06-06
US11912693B2 (en) 2024-02-27
BR112019026478A2 (pt) 2020-07-14
JP7252908B2 (ja) 2023-04-05
AU2024202449A1 (en) 2024-05-02
IL271149B2 (en) 2024-05-01
IL271149A (en) 2020-01-30
EP3638235A4 (de) 2021-06-09
AU2018282747B2 (en) 2024-01-18
CN110831593A (zh) 2020-02-21
KR20200020781A (ko) 2020-02-26
JP2020523390A (ja) 2020-08-06
US20210188826A1 (en) 2021-06-24
US20230234946A1 (en) 2023-07-27
EP3638235A1 (de) 2020-04-22

Similar Documents

Publication Publication Date Title
CA3066423A1 (en) Compounds for modulating s1p1 activity and methods of using the same
KR20140105445A (ko) 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
CA3149989A1 (en) Methods of treating epilepsy using the same
CA3027498A1 (en) Cxcr4 inhibitors and uses thereof
CN102325755A (zh) 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
CA3027495A1 (en) Cxcr4 inhibitors and uses thereof
EA031573B1 (ru) N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2
JP2012521428A (ja) 疼痛治療用のｐ２ｘ３受容体アンタゴニスト
BRPI0613491A2 (pt) antagonistas de piperazina-piperidina e agonistas do receptor de 5-ht1a
CN105517549B (zh) CaMKII抑制剂和其用途
TWI710554B (zh) 新穎苯并咪唑化合物及其醫藥用途
KR20200081424A (ko) 무스카린성 아세틸콜린 수용체 m4의 길항제
JP6054379B2 (ja) キナーゼをモジュレートするための組成物および方法
BR112018013955B1 (pt) Compostos ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido [2,3- d] azepina, composição farmacêutica que os compreende e uso dos mesmos
CA3052480A1 (en) 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
CA3052479A1 (en) 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
WO2014159938A1 (en) Substituted aminothiazoles for the treatment of tuberculosis
AU724646B2 (en) Method of treating common cold or allergic rhinitis
BG108114A (bg) Използване на gal3 рецепторни антагонисти за лечение на депресия и/или безпокойство
KR102633087B1 (ko) 신규한 융합헤테로고리-카르보노하이드라조노일 디시아나이드 화합물 및 이의 용도
JPH11510159A (ja) 抗けいれん剤としての未置換および置換ｎ−（ピロール−１−イル）ピリジンアミンの使用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230609

EEER Examination request

Effective date: 20230609

EEER Examination request

Effective date: 20230609